Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.

Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 21-85Biological sex: AllType: InterventionalSponsor: BioLite, Inc.Updated: Apr 20, 2026Locations: 1
Eligibility criteria

21 to 85 Years of age [+14]

Have a current or previous diagnosis of or history consistent with obsessive-com... [+12]

Read more
Status: Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Participants needed: 52
Trial details
Phase: Phase 2Age: 20+Biological sex: AllType: InterventionalSponsor: BioLite, Inc.Updated: Apr 13, 2026
Eligibility criteria

Age 20 or older, able to sign informed consent, understand and comply with proto... [+6]

Historical allergic events caused by mushroom. [+8]

Read more
Status: Not yet recruiting

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.

Participants needed: 44
Trial details
Phase: Phase 1, Phase 2Age: 20-70Biological sex: FemaleType: InterventionalSponsor: BioLite, Inc.Updated: Apr 13, 2026
Eligibility criteria

Females aged 20 - 70 years old at the time of signing the ICF. [+12]

Patient with brain metastasis. [+12]

Read more